Conference: 2007 PH Resource Network Symposium
Release Date: 10.12.2007
Presentation Type: Breakout Sessions
File Download: 2007 Symposium Oral therapies
Download Adobe Acrobat
Prior to 2001 there were no FDA approved oral therapies for PAH except calcium channel blockers. Bosentan was the first orally approved PAH specific medication. Since then the FDA has approved sildenafil and ambrisentan. these newer oral agents work by targeting different pathways. These medications will be reviewed along with the advantages, disadvantages, dosing and cost of each.